脑电生物反馈治疗躯体形式障碍的对照研究

A comparative study on the EEG biofeedback therapy for somatoform disorders

目的研究脑电生物反馈治疗躯体形式障碍的安全有效性。方法入组54例患者随机分为研究组(帕罗西汀联合脑电生物反馈治疗)和对照组(单用帕罗西汀治疗),治疗6周;采用症状自评量表(SCL-90)评定疗效,副反应量表(TESS)评定不良反应。结果治疗后2组SCL-90躯体化、抑郁、焦虑、恐怖、强迫各因子分较治疗前明显减少,研究组SCL-90躯体化、抑郁、焦虑因子分明显低于对照组(P<0.05),2组各时期TESS评分比较差异无统计学意义(P>0.05)。结论脑电生物反馈治疗联合帕罗西汀治疗躯体形式障碍疗效更为显著,不增加不良反应。

Objective To explore the security and efficacy of EEG biofeedback therapy on somatoform disorders. Methods 54 patients were randomly individed into study group （treated with paroxitine and EEG biofeedback therapy） and control group （treated with paroxitine alone） ,the treatment for 6 weeks, and the symptom checklist 90 （SCL--90） were used to as- sesse the efficacy , and adverse reactions were aassessed by the Treatment Emergent symptoms scale （TESS）. Results After treatment, the somatization,depression, anxiety, terrifying and obsession factor scores in SCL-90 were significantly lower than that before treatment; the somatixation , depression, anxiety factor scores of in study group were significantly lower than that of control group（P〈0.05）, TESS score of the two groups had no significant difference （P〉0.05）. Conclusion A combination of paroxitine and EEG biofeedback therapy would have better efficacy , without increasing adverse events on the treatmengt of somatoform disorders.